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Background: Nowadays, treatments for cholestasis remain largely nonspecific and often ineffective. Recent studies
showed that inflammatory injuries and oxidative stress occur in the liver with cholestasis. In this study, we would
use corilagin to treat the animal model of acute cholestasis in order to define the activity to interfere with
inflammation-related and oxidative stress pathway in cholestatic pathogenesis.
Methods: Rats were administrated with alpha-naphthylisothiocyanate to establish model of cholestasis and divided
into corilagin, ursodeoxycholic acid, dexamethasone, model and normal groups with treatment of related agent. At
24h, 48h and 72h time points after administration, living condition, serum markers of liver damage, pathological
changes of hepatic tissue, nuclear factor (NF)-kappaB, myeloperoxidase (MPO), malondialdehyde (MDA), superoxide
dismutase (SOD) and nitric oxide (NO) were examined and observed.
Results: Compared to model group, corilagin had remarkable effect on living condition, pathological manifestation
of liver tissue, total bilirubin, direct bilirubin, (P<0.01), but no effect on alanine aminotransferase (ALT) and aspartate
aminotransferase (AST). With corilagin intervention, levels of MPO, MDA and translocation of NF-κB were notably
decreased, and levels of SOD and NO were markedly increased (P<0.05 or P<0.01).
Conclusions: It is shown that corilagin is a potential component to relieve cholestasis through inflammation-
related and oxidation-related pathway.Background
Cholestasis is a reduction in bile flow that leads to the
intrahepatic accumulation of bile acids and other toxic
compounds with progression of liver pathology, includ-
ing hepatocellular injury and fibrosis [1]. Recent studies
have demonstrated that inflammatory injuries and oxida-
tive stress occur in the liver with cholestasis [2]. Inflam-
matory stimulators induce signaling pathways within
hepatocytes either directly, or through activation of
proinflammatory cytokines, which result in suppressed
expression and function of key hepatobiliary transporters
and repressed expression and activity of a large number
of nuclear transcriptional regulators, subsequently lead-
ing to rapid and profound reductions in bile flow [3].* Correspondence: chinesemd@hotmail.com
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reproduction in any medium, provided the orThis procedure enrolls neutrophils to accumulate in the
liver that evoke reactive oxygen species (ROS) to pro-
duce oxidative stress and liver injury [4].
Generally in clinical practice, treatments for cholesta-
sis remain largely nonspecific and often ineffective [5].
UDCA (ursodeoxycholic acid) is the therapeutic agent
most widely used for the treatment of cholestatic
hepatopathies [6]. Recent research indicated that UDCA
administration early after orthotopic liver transplant-
ation improved serum liver tests and decreased the
incidence of biliary sludge and cast within the 1st post-
operative year [7]. But it was concerned that further
studies should be needed evaluating a longer administra-
tion of UDCA that might be even more beneficial [8].
Further, in order to obtain an effect in acute cholestasis
in non-surgery condition, such as acute hepatitis, hepatic
failure or drug-induced hepatic injury, UDCA should
be combined with corticosteroids [9], which indicated
that UDCA was a limited choice in those diseases. An-
other effective is glucocorticoids. It was reported thatThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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within hours after bile duct ligation, which can enhance
the mitochondrial biogenesis and modulate the intrinsic
pathway of apoptosis following bile duct ligation [10].
But the side effects of glucocorticoids limit use in many
infection or bleeding-associated diseases.
Corilagin, a member of the tannin family with its molecu-
lar formula C27H22O18 [11], has been discovered in many
medicinal plants such as Phyllanthus speices etc. [12]. Re-
cent research indicated that corilagin has multiple activities
including antioxidative, antiinflammatory, antiapoptotic,
hepatoprotective and others. It was reported that corilagin
could attenuate tert-butyl hydroperoxide-induced oxidative
stress injury in microglial cells, which suggests that
corilagin should be a potential candidate for the treatment
of oxidative stress-induced neurodegenerative diseases [13].
It has been shown that corilagin has the potential to reduce
HSV-1-induced inflammatory insult to the brain [14] and
an anti-inflammatory activity in a cellular model [15]. Fur-
thermore, it was confirmed that corilagin is an inhibitor of
TNF-α [16] and can restrain radiation-induced microglia
activation via suppression of the NF-κB pathway [17], and
corilagin is protective against GalN/LPS-induced liver in-
jury through suppression of oxidative stress and apoptosis
[18]. Our recent research showed that corilagin can allevi-
ate the hepatic fibrosis caused by egg granuloma in
Schistosoma japonicum infection [19].
As nowadays there are no specific remedies for cholesta-
sis, while corilagin can alleviate the impairment caused by
inflammation and oxidation, we chose corilagin to treat
the animal model of acute cholestasis in order to define
the activity to interfere with inflammation-related and oxi-
dative stress pathway in cholestasis pathogenesis.
Methods
Chemicals and reagents
All chemicals were purchased from Gibco (Invitrogen,
city, country) or HyClone (Thermo Scientific, city, coun-
try) (like PBS and other basic stuff – this was an explan-
ation for the authors and should not appear in the text)
unless indicated otherwise. Affinity-purified rabbit anti-rat
NF-κB p65 was received from Santa Cruz Biotechnology
(Santa Cruz, CA). Biotin-conjugated goat anti rabbit IgG
and streptavidin-horseradish peroxidase (HRP) conjugate
were obtained from Kangcheng Biotech Company (Shang-
hai, China). Corilagin was provided by Dr. Jun-Yan Tao
and friendly offered by Prof. Ji-Kai Liu, Kunming Institute
of Botany, Chinese Academy of Science.
Animals
Male Sprague–Dawley rats weighing 200–220g were pur-
chased from the Experimental Animal Center of Tongji
Medical Colllege, Huazhong University of Science and
Technology. The rats were maintained under standardlaboratory conditions at a temperature of 25±2°C, a rela-
tive humidity of 50±15% and normal circadian rhythm
(12-h dark/12-h light). The animals were fed normal diet
and water ad libitum. All study protocols were approved
by internationally accepted principles and the Guidelines
for the Care and Use of Laboratory Animals of Huazhong
University of Science and Technology.Model and control establishment
90 rats were equally divided into 5 groups i.e. corilagin,
UDCA, dexamethasone, model and blank control groups.
Corilagin was prepared as 1.6% suspension; UDCA (Dr.
Falk Pharma GmbH, Freiburg, Germany) was prepared as
0.6% suspension with water; dexamethasone (Zhejiang
XianJu Pharmaceutical Company Ltd., Zhejiang, China)
was dissolved in water at a concentration of 0.045%; ANIT
(Sigma, St. Louis, MO) was dissolved in Sesame Oil at a
concentration of 1%. Before establishing the animal model,
corilagin (40 mg/kg/d), UDCA (60 mg/kg/d) and dexa-
methasone (1.8 mg/kg/d) were intragastrically adminis-
trated to the rats in respective group for 4 days. Model
and blank control were fed by normal saline. All groups
did not stop being administrated treating agent daily until
executed. At the 5th day after administration and fasting
for 12h, all group except normal control were intragas-
trically administrated ANIT (50mg/kg) for modeling. At
the same day, with 8h interval the rats were still fed by re-
spective drug or control agent. At 24h, 48h, 72h after
modeling, every 6 rats in each group were executed for
taking specimens. The living conditions of the victims
were observed as our previous study [20].Specimen collection
The procedure abided by our past experiment [21].
Following anesthesia with 6% chloral hydrate by intraperi-
toneal injection, the rat’s abdomen was opened and ab-
dominal aorta was separated. At the same time the
common bile duct was intubated for draining bile. Then
3ml arterial blood was collected in coagulant test tube.
Blood serum was obtained after 3250g centrifugation and
stored at −20°C until testing. Subsequently, rat’s liver was
cut by aseptic, RNase-free apparatus. After washing with
normal saline, the whole hepatic tissue was divided into
two parts: one was sheared and stored at −80°C, the other
was fixed in 10% formalin for 48h and then dehydrated,
followed by imbedding in paraffin and slicing.Serum markers of liver damage
The serumal total bilirubin, direct bilirubin, alanine
aminotransferase (ALT) and aspartate aminotransferase
(AST) were assayed by Aeroset Fully-auto Chemistry
Analyzer provided by Abbott Co LTD.
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Streptavidin-perosidase (SP) immunohistochemical assay
was employed to detect expression of the nuclear trans-
location of NF-κB. The slides of hepatic tissue were
soaked in 3% H2O2-methanol solution for 20 min in
order to block endogenous peroxydase. In the next 1%
Triton X-100 was added at 37°C for 5min, followed by
washing with PBS. After incubation with normal goat
serum at room temperature for 20 min, rabbit anti-rat
NF-κB p65 IgG antibody (1:200) was added dropwise
and the slides were stored at 4°C overnight. The next
day slides were washed with PBS and incubated with
biotin-conjugated goat anti rabbit IgG for 30 min at
37°C. After another washing with PBS streptavidin-HRP
was added and incubated for 30 min at 37°C. The slides
were thoroughly washed with PBS 3 times for 5 min and
stained with 3,3′-diaminobenzidine. Following normal
dehydration, lucidification and mounting the slides were
analysed under microscope (Olympus, Tokyo, Japan) as
specified in our previous studies [22-25] and digital
images were captured with camera (Olympus, Tokyo,
Japan).NO and oxidates assay
Myeloperoxidase (MPO), malondialdehyde (MDA), super-
oxide dismutase (SOD), and nitric oxide (NO) were quan-
tified by the respective assay kits (Nanjing Jiancheng
Bioengineering Institute, Nanjing, China) according to the
instructions of the manufacturer. The procedures were
also described in our previous studies [26,27].Purity determination of corilagin by HPLC
Purity of corilagin was determined by HPLC. The proced-
ure abided by our previous study [28,29]. Briefly, a
Hanbon-Kromasil 5μm C18 column was used at 30°C
with the wavelength of 268nm for detection. The mobile
phase was composed of 0.5% phosphoric acid and methyl
cyanide with a ratio of 76:24 and the injection volume was
10μl. Corilagin standard substance (purity>99%) was of-
fered by China National Institute for the Control of
Pharmaceutical and Biological Products. The purity of
corilagin was calculated to 62.14%. (Figure 1)Statistical analysis
Data were presented as mean ± S.D. Comparisons of
measurement data between multiple groups were
performed with one-way ANOVA test. Comparison of
the positive rate of NF-κBp65 between different groups
was carried out by Pearson chi-square tests. Statistical
significance was considered significant when P<0.05.
Whole process was performed with SPSS 12.0 software.Results
Living condition of the models
In normal group, the rats had clear urine and velvet and
glossy hair. The bile could be easily drained. When taken
out, the liver tissue was ruddy and lubricous. As com-
parison, it could be observed that the rats in model
group were inactive and anorectic. Their hair was in a
mess and urine was deep yellow. The drained bile
decreased and their liver lost ruddy and lubricous
appearance with a few of nodules at surface. The intes-
tinal canal of the model was distended or even of toxic
meteorism. Compared to model group, the rats in
corilagin group appeared more active and had more ap-
petite, more clear urine. The liver showed more ruddy
and lubricous appearance with fewer nodules at surface
with more easily drained bile, and the intestinal canal
was less distended. The rats in UDCA group showed
similar effect as corilagin group. The rats in dexametha-
sone group showed inactive state with proceeding weight
loss and mess hair. The color of urine was clearer than
that in model group, while hemorrhagic points emerged
at mucous membrane in eyes, nose, month and surface
of the liver. The bile in dexamethasone group could not
be drained easily and the intestinal canal was dilated like
that of model group.
Serum markers of liver damage
As shown in Figure 2, when compared with model con-
trol, corilagin had a significantly decreasing effect on
total bilirubin and direct bilirubin (P<0.01). At 24h, the
effect of corilagin on total bilirubin and direct bilirubin
was superior to that of UDCA but inferior to that of
dexamethasone, while at 48h corilagin was the most ef-
fective agent (P<0.01) but at 72h the three agents had
notable effect on total bilirubin and direct bilirubin level
(P<0.01) . Corilagin had no effect on serum aminotrans-
ferase release. UDCA showed an effect on 72h and dexa-
methasone was found to have an effect on 24h and 72h
on total bilirubin and direct bilirubin level (P<0.01).
Pathological manifestation of hepatic tissue
As shown in Figure 3, pathological features were differ-
ently presented in each group. In normal group, hepatic
tissue showed intact hepatic lobules, orderly liver cell
cord, hepatic cell with uniform stain, epithelial cells of
bile duct without damage, and no infiltration of neutro-
philic granulocyte. In model group, the liver tissue
showed typical pathological changes. At 24h, destruction
of hepatic lobules, hydropic degeneration or feather-like
degeneration in liver cells, swelling amotic bile duct
epithelial cell and infiltration of neutrophilic granulocyte
in portal area were observed. At 48h, the liver cells
showed more significantly swelling, cytoplasm with puff,
ununiformed nucleus with accumulative chromatin and

































































































































Figure 1 Purity determination of corilagin by high pressure/performance liquid chromatography (HPLC). A: The HPLC curve of corilagin
standard substance; B: The HPLC curve of corilagin sample. Purity of corilagin was determined by HPLC. A Hanbon-Kromasil 5μm C18 column
was used at 30°C with the wavelength of 268nm for detection. The mobile phase was composed of 0.5% phosphoric acid and methyl cyanide
with a ratio of 76:24 and the injection volume was 10μl. The purity of corilagin was calculated to 62.14%.
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showed plenty of punctiform or focused necrotic zones
and proliferation of Kupffer cells and bile duct epithelial
cells all over the visual field. The bile duct exhibited a
constrictive canal with necrotic cells and bile thrombus.
Many necrotic hepatocytes and infiltrated neutrophils
were present around the bile duct. At 72h, the patho-
logical changes were recovered slightly but still featured
with necrotic regions and neutrophil infiltration. In the
corilagin group the pathological changes were signifi-
cantly lower than in the model group. The manifesta-
tions in the UDCA group were a little severer than in
the corilagin group while in the dexamethasone group
the pathological impairment appeared more aggravated.
Expression of NF-κBp65 examined by
immunohistochemistry
As shown in Figure 4, it was shown that in normal
group the staining of NF-κBp65 in nucleus was not re-
markable. After ANIT administration, the positive rateof NF-κBp65 staining in nucleus significantly rose
(P<0.01). With corilagin treatment, the rate of NF-κBp65
staining in nucleus was decreased markedly (P<0.01). In
UDCA and dexamethasone group the rate was also sig-
nificantly lower than that in model group but higher
than that in corilagin group (P<0.05).
Levels of MPO, MDA, SOD and NO in tissue
As shown in Figure 5, the level of MPO and MDA sig-
nificantly rose in the model group (P<0.01). At all-time
points the levels of the two enzymes were notably down-
regulated by corilagin treatment and even lower than
the normal level. As control, UDCA had no similar
effect as corilagin, and dexamethasone only had an effect
on MDA at 72h (P<0.05). In contrast, the levels of SOD
and NO in tissue decreased notably after ANIT stimula-
tion (P<0.05 or P<0.01, respectively), while in the
corilagin group the levels of SOD and NO were remark-
ably elevated (P<0.05 or P<0.01, respectively). UDCA
had not the same effects except for SOD at 48h.
AB
** **
Figure 2 Effect of corilagin on Liver Functional Test at 24h, 48h, 72h. A: On Total Bilirubin; B: On Direct Bilirubin.The data were shown as
mean±SD; *p<0.05 compared to model group; **p<0.01 compared to model group. When compared with model control, corilagin had a
significantly decreasing effect on total bilirubin and direct bilirubin (P<0.01). At 24h, the effect of corilagin on total bilirubin and direct bilirubin
was superior to that of UDCA but inferior to that of dexamethasone, while at 48h corilagin was the most effective agent (P<0.01) but at 72h the
three agents had notable effect on total bilirubin and direct bilirubin level (P<0.01) . UDCA showed an effect on 72h and dexamethasone was
found to have an effect on 24h and 72h on total bilirubin and direct bilirubin level (P<0.01).
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48h, and on NO at 24h and 72h (P<0.05 or P<0.01,
respectively).
Discussion
Cholestasis is characterized by impaired bile flow, reduc-
tion of bile acids in the intestine, and retention of bile
acids in the liver. Rats taken in alpha naphthyliso-thiocyanate (ANIT) have been one of the most common
experimental models of intrahepatic cholestasis and used
extensively, which was permitted to describe not only
cholestatic alterations but also compensatory mecha-
nisms [30]. The liver in ANIT-treated rats showed
cholangiolitic hepatitis characterized by intrahepatic
cholestasis, necrosis of hepatocytes and biliary epithelial




Figure 3 Effect of corilagin on pathological manifestation of hepatic tissue at 48h. A: Corilagin group; B: UDCA group; C: Dexamethasone
group; D: Model group; E: Normal group. In normal group, hepatic tissue showed intact hepatic lobules, orderly liver cell cord, hepatic cell with
uniform stain, epithelial cells of bile duct without damage, and no infiltration of neutrophilic granulocyte. In model group, the liver tissue showed
typical pathological changes. At 48h, the liver cells showed more significantly swelling, cytoplasm with puff, ununiformed nucleus with
accumulative chromatin and enlarged, strong-stained nucleolus. The liver tissue showed plenty of punctiform or focused necrotic zones and
proliferation of Kupffer cells and bile duct epithelial cells all over the visual field. The bile duct exhibited a constrictive canal with necrotic cells
and bile thrombus. Many necrotic hepatocytes and infiltrated neutrophils were present around the bile duct. In the corilagin group the
pathological changes were significantly lower than in the model group. The manifestations in the UDCA group were a little severer than in the
corilagin group while in the dexamethasone group the pathological impairment appeared more aggravated.
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hepatobiliary diseases is accomplished by measuring
serum concentrations of bile acids and bilirubin as well
as serum activities of liver-associated enzymes which re-
veal information about the state of liver. Our previous
study showed that the indexes of liver damage and
pathological changes start to rise at 24h after ANIT
treatment, reach a maximum at 48h and trend to restore
at 72h [21]. The data of the present study imply that the
most effective change after corilagin treatment refers to
bilirubin, both total and direct. Compared to UDCA and
dexamethasone, corilagin showed a protective effect on
the elevation of serum bilirubin after hepatic injury.
However, there is no obvious evidence of corilagin to al-
leviate aminotransferases, which indicates that corilagin
has a stronger effect on relieving bile or bile duct
disorders.The ANIT hepatotoxicity is attributed to both gluta-
thione and blood neutrophils. Glutathione can form a
reversible S-conjugate with ANIT that is critical in shut-
tling ANIT into bile, where it induces a group of toxic
substances[32], and neutrophils may be activated during
ANIT exposure to release cytotoxic proteases that cause
injury to target cells [33]. In our study, with ANIT treat-
ment the rat liver showed typical damage of neutrophilic
infiltration, necrosis of hepatocytes, proliferation of in-
flammatory cells and epithelial cells of bile duct and for-
mation of bile thrombus. By corilagin intervention, it
could be observed that improvement of the acute hep-
atic impairment was achieved, which shows the protect-
ive effect of corilagin on hepatic pathology.
ANIT-evoked hepatotoxins cause severe neutrophilic
inflammation around portal tracts and bile ducts and in-




Figure 4 Effect of corilagin on NF-κBp65 expression at 48h. The activated NF-κBp65 presented brown stain in nuclear and inactivated
NF-κBp65 presented brown in cytoplasm. A: Corilagin group; B: UDCA group; C: Dexamethasone group. D: Model group; E: Normal group. It
was shown that in normal group the staining of NF-κBp65 in nucleus was not remarkable. After ANIT administration, the positive rate of
NF-κBp65 staining in nucleus significantly rose (P<0.01). With corilagin treatment, the rate of NF-κBp65 staining in nucleus was decreased
markedly (P<0.01). In UDCA and dexamethasone group the rate was also significantly lower than that in model group but higher than that in
corilagin group (P<0.05).
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in cholestatic hepatitis. Nuclear factor-kappa B (NF-κB)
is a pivotal factor that transfers inflammatory signals
from cytoplasm into the nucleus and induces a series of
inflammatory responses in the cell [34,35]. In our
present study, it was found that NF-κB was notably
suppressed in the corilagin group, which demonstrates
that corilagin has the efficacy to control inflammatory
injuries during cholestasis in the liver.
The reactive oxygen species are generated by aerobic
metabolism and environmental stressors. They can
chemically modify proteins and alter their biological
functions and, if the repair processes fail, oxidized
proteins may become cytotoxic [36]. Myeloperoxidase
(MPO), a heme-containing peroxidase abundantly
expressed in neutrophils and monocytes, while produces
the powerful oxidant hypochlorous acid and is a key
contributor to the oxygen-dependent microbicidal activ-
ity of phagocytes, is linked to tissue damage in manydiseases when it is excessive to generate MPO-derived
oxidants [37]. In our research, corilagin displayed a
strong effect on MPO, demonstrating the oxidative im-
pairment of neutrophils can be prevented by corilagin.
Malondialdehyde (MDA) is the principal and most stud-
ied product of polyunsaturated fatty acid peroxidation.
So far, oxidative stress have been assessed by measuring
the level of antioxidants or the concentration of sub-
stances derived from the action of oxygen free radicals
on biological molecules, and measurement of MDA is
considered an effective marker of oxidative stress in a
biological sample [38]. In our study, it could be showed
that corilagin has a significant effect on MDA expres-
sion, which implies corilagin has a strong potential to
suppress oxidative stress when cholestasis occurs. After
oxidative stress occurs, products of lipid peroxidation
created in different biochemical reactions are normally
removed by antioxidants, the compounds that are in-




Figure 5 Effect of corilagin on anti-oxidative and nitric oxide at 24h, 48h, 72h. A: On myeloperoxidase; B: On malondialdehyde; C: On
superoxide dismutase; D: On nitric oxide. The data were shown as mean±SD; *p<0.05 compared to model group; **p<0.01 compared to model
group. The level of MPO and MDA significantly rose in the model group (P<0.01). At all-time points the levels of the two enzymes were notably
down-regulated by corilagin treatment and even lower than the normal level. As control, UDCA had no similar effect as corilagin, and
dexamethasone only had an effect on MDA at 72h (P<0.05). In contrast, the levels of SOD and NO in tissue decreased notably after ANIT
stimulation (P<0.05 or P<0.01, respectively), while in the corilagin group the levels of SOD and NO were remarkably elevated (P<0.05 or P<0.01,
respectively). UDCA had not the same effects except for SOD at 48h. Dexamethasone had an up-regulating effect on SOD at 48h, and on NO at
24h and 72h (P<0.05 or P<0.01, respectively).
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[39]. The most important enzymatic antioxidants are
superoxide dismutase (SOD), a sort of enzyme that
catalyze the dismutation of superoxide radical into
hydrogen peroxide (H2O2) and molecular oxygen (O2)
and consequently present an important defense mechan-
ism against superoxide radical toxicity [40]. In the
present research, the SOD level in corilagin group was
markedly higher than that in model group, which
showed the anti-oxidative effect of corilagin.
Nitric oxide (NO) plays a critical role on hepatic me-
tabolism whether liver is in normal condition or in in-
jury by different agents. Although some experiments
show controversial effect of NO in the liver on patho-
logical condition, literature from the past 15 years seems
to reinforce the consensus that NO is indeed protective.
Some of the protective actions of NO are due to its po-
tential as an antioxidant and anti-inflammatory agent,
along with its beneficial effects on cell signaling and in-
hibition of nuclear proteins, such as NF-kappa B and
AP-1, especially when ischemia occurs [41,42]. The sup-
plementation with a NO donor prevented caspase-3 ac-
tivity and apoptosis induced by bile acids in cultured rat
hepatocytes [43]. In our experiment, after corilagin treat-
ment the expression of NO rose notably, which implies
corilagin can improve circulation in the liver.
Corilagin has been found in many medicinal plants
and some advanced technologies have been employed to
detect the content of corilagin in those plants [44]. Al-
though corilagin can be synthesized by chemicals, the
actual output for synthesis is limited [11]. Thereby some
novel techniques were used to purify corilagin from
plants [45]. In our research, we identified the content of
corilagin in extraction and the purity of corilagin is
dominant in the extraction.
Conclusions
In conclusion, we found that corilagin has the capability
to ensure hepatic protection, to block NF-κB pathway,
to provide anti-oxidative effects and to improve hepatic
circulation in experimental intrahepatic cholestasis,
which suggests that corilagin is a putative medication to
treat cholestasis. It is shown that corilagin has the
potential to cure inflammation-related and oxidation-
related diseases. The further proceeding might be to
investigate how corilagin interacts with the inflammatory
and oxidative signal pathways in cell and animal models.
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